Navigation Links
West Announces Agreement with Janssen Biotech to Develop and Commercialize a New Self-injection Technology
Date:9/4/2012

LIONVILLE, Pa., Sept. 4, 2012 /PRNewswire/ -- West (NYSE: WST), a leading global manufacturer of components and systems for injectable drug delivery, today announced an agreement with Janssen Biotech, Inc. to collaborate on the development and manufacturing of an innovative self-injection product. The technology, developed by Janssen Biotech, has been specifically designed to meet the needs of patients by facilitating easier self-injection of pharmaceutical and biologic drug products. West will market the new injection technology under the name SelfDose™ (http://www.selfdose.com/).

(Logo: http://photos.prnewswire.com/prnh/20120904/NE65950LOGO )

West will be responsible for co-developing and handling the commercial scale-up and manufacture of the product, and will have the ability to offer the SelfDose injection technology as part of its expanding portfolio of self-injection technology platforms. The SelfDose injection technology complements West's ConfiDose® and SmartDose® injection technologies, and offers a solution for improved manual injection.

Providing the best solution to the challenges of packaging and delivering today's sensitive and complex biopharmaceutical products requires not only an effective drug container, but also a delivery system that can enable safe, effective and reliable delivery of the medication, especially when the administrator may be a patient. The SelfDose injection technology can help meet these challenges.

"We are delighted to have formalized our relationship with Janssen Biotech around this drug delivery platform and look forward to working together to commercialize the SelfDose injection technology, providing manufacturing, development and regulatory support through the remainder of the process," said Donald E. Morel, Jr., Ph.D., West's Chairman and CEO. "We value the opportunity to strengthen our long-standing relationship and are excited by this agreement. We look forward to working with Janssen to help them meet their business goals to restore health and serve patients."

About West

West's innovative system, device and component solutions help improve the safety and administration of injectable drugs. West's proprietary materials science, formulation research and manufacturing technologies advance the quality, therapeutic value, development speed and rapid market availability of pharmaceuticals, biologics and vaccines. Sales in 2011 totaled US$1.2 billion. West supports its customers from sales, manufacturing, customer support and research and development from locations in North and South America, Europe, Asia and Australia. Global headquarters are in Lionville, Pa., USA. Visit West online at http://www.westpharma.com. Follow West on Twitter: http://www.twitter.com/WestPharma

SelfDose™ is a trademark of West.

ConfiDose® is a registered trademark of West Pharmaceutical Services, Inc. in the United States and other jurisdictions.

SmartDose® is a registered trademark of Medimop Medical Projects Ltd., a subsidiary of West Pharmaceutical Services, Inc.

Media Contact:
Kristin Villiotte
Schwartz MSL
(781) 684-0770
westpharma@schwartzmsl.com

Investor Contact:
Michael A. Anderson
Vice President and Treasurer
(610) 594-3345
Michael.Anderson@westpharma.com

 


'/>"/>
SOURCE West
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
2. TeleTracking Announces Real-Time Locating System (RTLS) Contract with Geisinger Health
3. VirtualScopics Announces Receipt of Notice from Nasdaq
4. VLST Corporation Announces In-licensing Agreement with Pfizer for Anti-CD40 Monoclonal Antibody
5. Sihuan Pharmaceutical Announces 2012 Interim Results
6. Pro-Dex, Inc. Announces Fiscal 2012 Fourth Quarter and Full-Year Financial Results Conference Call and Webcast
7. Elbit Imaging Ltd. Announces Second Quarter Results for 2012
8. SkinMedica Announces Collaboration Agreement with Massachusetts General Hospital for Research and Development of Pigmentation Products
9. Lilly Announces Retirement of Robert Armitage, Names Michael Harrington Senior Vice President and General Counsel
10. Janssen Biotech Announces Global License and Development Agreement for Investigational Anti-Cancer Agent Daratumumab
11. MAP Pharmaceuticals, Inc. Announces Full Exercise of Underwriters Option to Purchase Additional Shares of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... 2016  Palatin Technologies, Inc. ("Palatin") (NYSE MKT: ... previously disclosed underwritten public offering of units with ... sole book-running manager, Roth Capital Partners acted as ... co-manager for the offering. "This financing ... proceeds, allowing us to continue advancing bremelanotide for ...
(Date:12/7/2016)... Md. , Dec. 7, 2016  Northwest ... or the "Company"), a biotechnology company developing DCVax® ... announced that the Nasdaq Staff has not accepted ... of Listing Rules previously reported, and the Company ... withdraw the Company,s common stock from listing on ...
(Date:12/7/2016)... , December 7, 2016 ... Trial Management System (CTMS) Market, by Components (Software, ... Site), End-users (Pharmaceutical and Biotechnology Companies, Clinical Research ... Share, Size and Forecast to 2022", published by ... system (CTMS) market is expected to grow at ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... , ... AlignLife clinics nationwide are giving back to their communities by collecting ... bountiful gifts wrapped tightly under a Christmas Tree. AlignLife hopes to spread the ... , In exchange for generous donations, customers will receive a gift in return. ...
(Date:12/7/2016)... ... 2016 (PRWEB) (PRWEB) December 07, 2016 , ... Man’s best ... Dermatitis Associated with Borrelia Infection” reveals that a condition similar to ... prestigious Journal of Veterinary Science & Medical Diagnosis. , Morgellons disease is an ...
(Date:12/7/2016)... ... December 07, 2016 , ... The Honolulu cosmetic ... redesigned website, which launched October 17, 2016, features comprehensive information regarding a wide ... layout. Visitors and patients can discover the latest clinical dermatology treatments for medical ...
(Date:12/7/2016)... ... December 07, 2016 , ... Delete® - Tattoo Removal and Laser ... Holiday Party Season. Save Up To 33% Off Botox® and Juvederm® Products Now Through ... Phoenix Valley with Delightful Deals on Botox® and Juvederm® just in time ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... Campaign Winner in the Folio: Marketing Awards competition. Live From won in the ... in pioneering, inventive, and ultimately successful projects undertaken by the media industry’s most ...
Breaking Medicine News(10 mins):